82 related articles for article (PubMed ID: 15370201)
1. Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain.
Riccioni R; Rossini A; Calabrò L; Diverio D; Pasquini L; Lococo F; Peschle C; Testa U
Leuk Lymphoma; 2004 Aug; 45(8):1511-7. PubMed ID: 15370201
[TBL] [Abstract][Full Text] [Related]
2. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.
Riccioni R; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Ottone T; Foà R; Testa U
Br J Haematol; 2009 Feb; 144(3):376-87. PubMed ID: 19036083
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-3 receptor in acute leukemia.
Testa U; Riccioni R; Diverio D; Rossini A; Lo Coco F; Peschle C
Leukemia; 2004 Feb; 18(2):219-26. PubMed ID: 14671644
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.
Testa U; Riccioni R; Militi S; Coccia E; Stellacci E; Samoggia P; Latagliata R; Mariani G; Rossini A; Battistini A; Lo-Coco F; Peschle C
Blood; 2002 Oct; 100(8):2980-8. PubMed ID: 12351411
[TBL] [Abstract][Full Text] [Related]
5. Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts.
Riccioni R; Diverio D; Mariani G; Buffolino S; Riti V; Saulle E; Petrucci E; Cedrone M; Lo-Coco F; Foà R; Peschle C; Testa U
Stem Cells; 2007 Aug; 25(8):1862-71. PubMed ID: 17446561
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
Leuk Lymphoma; 1994 Dec; 16(1-2):79-88. PubMed ID: 7535143
[TBL] [Abstract][Full Text] [Related]
7. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
Yalcintepe L; Frankel AE; Hogge DE
Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
[TBL] [Abstract][Full Text] [Related]
8. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations.
Riccioni R; Pelosi E; Riti V; Castelli G; Lo-Coco F; Testa U
Br J Haematol; 2011 Apr; 153(1):33-42. PubMed ID: 21332708
[TBL] [Abstract][Full Text] [Related]
10. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts.
Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W
Leukemia; 1996 Oct; 10(10):1584-91. PubMed ID: 8847893
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication.
Muñoz L; Aventín A; Villamor N; Juncà J; Acebedo G; Domingo A; Rozman M; Torres JP; Tormo M; Nomdedéu JF
Haematologica; 2003 Jun; 88(6):637-45. PubMed ID: 12801839
[TBL] [Abstract][Full Text] [Related]
12. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
13. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication.
Kussick SJ; Stirewalt DL; Yi HS; Sheets KM; Pogosova-Agadjanyan E; Braswell S; Norwood TH; Radich JP; Wood BL
Leukemia; 2004 Oct; 18(10):1591-8. PubMed ID: 15343344
[TBL] [Abstract][Full Text] [Related]
14. MEG-01s cells have receptors for and respond to IL-3, IL-6, and SCF.
Kellar KL; Hooper WC; Benson JM
Exp Hematol; 1995 Jun; 23(6):557-64. PubMed ID: 7539384
[TBL] [Abstract][Full Text] [Related]
15. Cell surface expression of c-kit receptors by childhood acute myeloid leukemia blasts is not of prognostic value: a report from the Childrens Cancer Group.
Smith FO; Broudy VC; Zsebo KM; Lampkin BC; Buckley CV; Buckley JD; Opie T; Woods WG; Hammond GD; Bernstein ID
Blood; 1994 Aug; 84(3):847-52. PubMed ID: 7519080
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
Lin LI; Chen CY; Lin DT; Tsay W; Tang JL; Yeh YC; Shen HL; Su FH; Yao M; Huang SY; Tien HF
Clin Cancer Res; 2005 Feb; 11(4):1372-9. PubMed ID: 15746035
[TBL] [Abstract][Full Text] [Related]
17. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
18. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
[TBL] [Abstract][Full Text] [Related]
19. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML.
Macedo A; Orfao A; Martínez A; Vidriales MB; Valverde B; López-Berges MC; San Miguel JF
Br J Haematol; 1995 Feb; 89(2):338-41. PubMed ID: 7532985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
